Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Aspergillosis Treatment Market

Aspergillosis Treatment Market Share

Report ID: GMI9917
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Aspergillosis Treatment Market Share

The aspergillosis treatment sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.

Aspergillosis Treatment Market Companies

Some of the eminent market participants operating in the aspergillosis treatment industry include:

Abbott Laboratories
Astellas Pharma Inc.
Astra Zeneca PLC
Basilea Pharmaceutica Ltd.
Bayer AG
Endo International plc
F2G
GSK plc
Johnson & Johnson
Merck & Co., Inc.
Mayne Pharma Group Limited
Novartis AG
PULMATRiX, Inc.
Takeda Pharmaceutical Company Ltd.
Viatris Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global aspergillosis treatment industry was valued at USD 3.8 billion in 2023 and is anticipated to register 4.3% CAGR between 2024 and 2032 due to the rising incidence of aspergillosis and growing awareness of fungal infections.

The hospital pharmacies segment in the market is forecasted to reach USD 3 billion by 2032 due to comprehensive antifungal inventories and specialized pharmacists optimizing therapy for complex infections like aspergillosis.

The antifungal drugs segment in the aspergillosis treatment market accounted for USD 2.4 billion in 2023 due to the efficacy of azoles, echinocandins, and polyenes in treating aspergillosis and their versatile formulations for tailored therapies.

Abbott Laboratories, Astellas Pharma Inc., Astra Zeneca PLC, Basilea Pharmaceutica Ltd., Bayer AG, Endo International plc, F2G, GSK plc, Johnson & Johnson, Merck & Co., Inc., and Mayne Pharma Group Limited, among others